Myriad Genetics Inc (MYGN)
Healthcare
Diagnostics & Research
3.00 $
+5.6%
vs. previous close
Closing price · As of: 3. Aug 2026
Myriad Genetics Inc (MYGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -8.3 million $. Tick rows to compare them in a chart.
| Tick rows to compare them in a chart (up to 4) | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22 | -55 | -19 | 2.6 | 0.7 | 6.6 | -16 | -14 | 21 | 11 | -16 | -8.3 | 7.7 | |
| 14 | 15 | 16 | 15 | 16 | 15 | 14 | 14 | 13 | 13 | 13 | 13 | 50 | |
| 12 | 10 | 12 | 15 | 12 | 11 | 9.5 | 11 | 12 | 2.8 | 6.5 | 7.2 | 29 | |
| -6.5 | -41 | -21 | -2.3 | -7.3 | -24 | -12 | -27 | 21 | -1.6 | -8.2 | 13 | 25 | |
| 18 | 14 | 8.6 | 8.9 | 6.3 | 5.9 | 5.3 | 6.9 | 2.8 | 6.0 | 5.4 | 2.1 | 16 | |
| -2.5 | -12 | -7.1 | -6.4 | 7.5 | -5.9 | -8.3 | -6.9 | -6.2 | -6.0 | -6.5 | -3.2 | -22 | |
| -2.2 | – | – | – | -3.0 | – | – | – | -0.3 | – | – | – | – | |
| – | – | – | – | -0.1 | 0.4 | 19 | -0.1 | 65 | 0.1 | -0.1 | – | – | |
| -2.5 | 122 | -8.8 | 2.4 | -3.1 | 2.1 | 14 | 2.6 | 56 | -8.2 | -3.0 | 2.2 | 47 | |
| -28 | 56 | -35 | -4.4 | 8.6 | 2.1 | -11 | -17 | 71 | -3.5 | -25 | -9.2 | 33 | |
| -40 | -68 | -27 | -6.3 | -5.6 | 0.7 | -22 | -21 | 18 | 4.6 | -21 | -10 | -8.6 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.